| Literature DB >> 34198652 |
Chia-Jung Li1,2, Yen-Dun Tony Tzeng3,4, Yi-Han Chiu5, Hung-Yu Lin6, Ming-Feng Hou7, Pei-Yi Chu8,9,10,11.
Abstract
Triple negative breast cancer (TNBC) is a heterogeneous tumor characterized by early recurrence, high invasion, and poor prognosis. Currently, its treatment includes chemotherapy, which shows a suboptimal efficacy. However, with the increasing studies on TNBC subtypes and tumor molecular biology, great progress has been made in targeted therapy for TNBC. The new developments in the treatment of breast cancer include targeted therapy, which has the advantages of accurate positioning, high efficiency, and low toxicity, as compared to surgery, radiotherapy, and chemotherapy. Given its importance as cancer treatment, we review the latest research on the subtypes of TNBC and relevant targeted therapies.Entities:
Keywords: biomarkers; breast cancer; pathogenesis; target therapy
Year: 2021 PMID: 34198652 DOI: 10.3390/cancers13122978
Source DB: PubMed Journal: Cancers (Basel) ISSN: 2072-6694 Impact factor: 6.639